Bod Australia has changed its name to Bod Science in a move to better reflect its geographic reach and underline the drug-development focus of the business.

Shareholders overwhelmingly approved the switch at its annual general meeting with the company formally adopting the new name this week.

Bod has retained its logo, but swapped Australia for Science in its branding

Chief executive Jo Patterson said Bod has outlived its ‘Australia’ moniker, with the new branding more accurately depicting the positioning of the company.

“Bod Australia probably doesn’t reflect the focus that we have as a global player, and we already have a presence in many other markets,” Patterson told Cannabiz.

“We also define ourselves as a drug developer and product innovator with foundations in R&D and our clinical trial work, and that is better reflected in Bod Science.

“We felt that changing the name is appropriate and a good reflection of where we are playing, and our vision.”

That vision is to become “a billion-dollar life science and global healthcare company by 2031”, Patterson said.

“I also think there might be an underlying influence of a name like Bod Science. It will perhaps get shareholders to think about us slightly differently,” she added. “Of course we share the strategies and execution of that strategy, but I think this brings it to life.”

Meanwhile, senior management will fly to San Francisco in January to present at the JP Morgan annual healthcare conference.

Jo Patterson: heading to San Francisco for the JP Morgan healthcare conference

Patterson said it will give the company a global platform to showcase its newly acquired Aqua Phase technology.

“It’s a super exciting opportunity,” she said. “Importantly, this will get Bod on the radar of both the big US companies who are interested in this space and the issue of solubility of CBD, and then of course investors – not that we are looking for funding.

“I want the eyeballs on what we are doing and the global platform is where we need to be.

“There is huge interest in the solubility of CBD and bioavailability and the enormous opportunity it unlocks.”

  

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...

Leave a comment